Edward Wolin, MD, senior faculty, hematologist-oncologist, and director of the Center for Carcinoid and Neuroendocrine Tumors, at Mount Sinai, discusses the current treatment landscape of neuroendocrine tumors (NETs).

NETs affect approximately 5 in every 100,000 people in the United States, Wolin says. Moreover, the incidence of NETs has risen over the past 30 years. 

Currently, multiple treatment options are available for patients with NETs, including somatostatin analogs, Wolin explains.

Additionally, biologic agents, such as everolimus (Afinitor), are available, says Wolin. These systemic agents can be thought of as targeted chemotherapies. 

Other options include the radiopharmaceutical Lutathera (lutetium-177 dotatate), surgical resection, interventional radiation, tumor ablation of the liver, and radioembolization of the hepatic artery, concludes Wolin.

Videos

Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.  



Dr. Wolin on the Treatment Landscape of NETs 

Edward Wolin, MD, senior faculty, hematologist-oncologist, and director of the Center for Carcinoid and Neuroendocrine Tumors at Mount Sinai, discusses the safety profile of 

in patients with advanced neuroendocrine tumors (NETs).

In the US Expanded Access Program trial, investigators assessed the long-term toxicity of Lutathera in patients with advanced, somatostatin receptor–positive NETs. The trial had an average follow-up of 130.8 days at the time of data analysis presented during the 

Results showed that the most commonly reported toxicities with the agent were mild, says Wolin. Severe toxicities of grade 3 or 4 were extremely uncommon, with few patients experiencing life-threatening toxicities. The most common grade 1 or 2 toxicities included nausea, which occurred in 93% of patients, and vomiting, which was reported in 41% patients. However, in almost all cases, these toxicities were not caused by the

 the study drug; rather, they were linked with the amino acids that were used to protect patients' kidneys, according to Wolin.

At one point on the trial, many patients switched from the initial amino acid regimen to a new amnio acid regimen, which was found to protect the kidneys equally well without nausea, adds Wolin. The other toxicities that were reported included fatigue, in 28% of patients, and thrombocytopenia, in 18% of patients. Only 1% of patients experienced severe treatment-related toxicities. It was very rare for patients to experience carcinoid crisis (0.3%) or severe vomiting that lead to dehydration (0.3%), concludes Wolin.

Edward Wolin, MD, discusses the safety profile of 177Lu-dotatate in patients with advanced neuroendocrine tumors.


Edward Wolin, MD

Articles

Dr. Wolin on the Treatment Landscape of NETs

Dr. Wolin on the Safety of Lutathera in Advanced NETs